Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
04-09-01 Monoamine-oxidase-B inhibitors
| Selegiline Hydrochloride |
|
First Choice
|
Tablets 5mg, 10mg Parkinson's disease. See BNF for information on dose equivalence and conversion between tablet and lyophilisate formulations. |
|
Links
BNF: Parkinson’s disease- How do you convert from co-beneldopa (Madopar®) prolonged-release capsules to dispersible tablets?
LSCMMG: Apomorphine shared care guideline- LSCMMG: Opicapone NMR
- LSCMMG: Opioid reduction: best interests opioid reduction position statement
- LSCMMG: OpioId treatment: patient-prescriber opioid treatment agreement
- LSCMMG: Restless Legs Syndrome in Adults in Primary Care
- LSCMMG: Restless Legs Syndrome in Adults in Primary Care
- LSCMMG: Restless Legs Syndrome in Adults in Primary Care
- MHRA Drug Safety Update April 2016: Apomorphine with domperidone: minimising risk of cardiac side effects
- MHRA: Apomorphine with domperidone: minimising risk of cardiac side effects
- MHRA: Dopamine agonists: pathological gambling, increased libido, and hypersexuality
- MHRA: Recent drug-name confusion
- MHRA: Recent drug-name confusion
- NICE CKS: Parkinson’s disease
- NICE NG71: Parkinson’s disease in adults
- NICE TA934: Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
- NICE TA934:Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
- Shared Care Guideline - Apomorphine